Selected Grants
Retinal Light Scattering Measurements as a Clinical Biomarker of Alzheimer's Disease
ResearchCo Investigator · Awarded by National Institute on Aging · 2022 - 2027Cognitive Training to Reduce Cognitive Impairment: The PACT Trial
ResearchPhysician · Awarded by University of South Florida · 2021 - 2026Open-Label Extension of Studies ATH-1017-0201 and ATH-1017-0202 in Subjects with Mild to Moderate Alzheimer¿s Disease
Clinical TrialPrincipal Investigator · Awarded by Athira Pharma, Inc. · 2021 - 2026Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)"
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2020 - 2025Improving the lives of persons living with dementia and their families through person-centered measurement of home time
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2025Combination anti-amyloid therapy for preclinical Alzheimer's disease
Clinical TrialPrincipal Investigator · Awarded by University of Southern California · 2019 - 2025Assessing the feasibility and acceptability of a Time Restricted Feeding intervention among older adults with Mild Cognitive Impairment
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2025Pesticides, Olfaction, and Prodromal Neurodegeneration Among US Farmers
ResearchInvestigator · Awarded by Michigan State University · 2019 - 2025A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by Athira Pharma, Inc. · 2021 - 2024AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects W
Clinical TrialPrincipal Investigator · Awarded by Eisai, Inc. · 2020 - 2024The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
Clinical TrialPrincipal Investigator · Awarded by University of Southern California · 2019 - 2024A 72-Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease (AD) (Stage 3 AD) to Evaluate the Effect on Cognitive and Functional Impairment, Safety, and Tolerabilit
Clinical TrialPrincipal Investigator · Awarded by Neuraly · 2021 - 2023An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2019 - 2022A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2016 - 2021A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2017 - 2021Alzheimer's Disease, Genes, and Pesticide Use in the Agricultural Health Study
ResearchInvestigator · Awarded by National Institutes of Health · 2014 - 2021A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2016 - 2020Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals
Clinical TrialInvestigator · Awarded by Brigham and Women's Hospital · 2015 - 2020A Blinded Longterm Ext Study to Eval the Safety and Efficacy of Pioglitazone (AD-4833 Sust Release 0.8 mg daily) to Slow the Progress of Cog Decline in Subj Who Have completed the AD4833/TOMM40_301 Study w/ Diag of Mild Cog Impair due to Alz Disease.
Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceuticals North America Inc. · 2015 - 2019A Phase III Clinical Trial to Study the Efficacy & Safety of MK-8931 (SCH900931) in subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2016 - 2019A DB, Randomized, Placebo Controlled, Parallel Group Study to Qualify a Biomarker Algorithm for Risk of Developing MCI due to AD and to Test the S&E of Pioglitazone (AD-4833 SR 0.8 mg QD) Delay Onset of MCI due AD in Cognitively Normal Subjects.
Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceuticals North America Inc. · 2013 - 2019A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Clinical TrialPrincipal Investigator · Awarded by Eisai, Inc. · 2017 - 2018Lifestyle, CVD Risk and Cognitive Impairment
ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2018Caregivers' Reactions and Experience: Imaging Dementia - Evidence for Amyloid Scanning - CARE IDEAS
ResearchCo Investigator · Awarded by Brown University · 2016 - 2017Novel Retinal Biomarkers for Early Detection of Alzheimer's Disease
ResearchCo Investigator · Awarded by Alzheimer's Association · 2013 - 2016IPA - John F Ervin
ResearchPrincipal Investigator · Awarded by Durham Veterans Affairs Medical Center · 2013 - 2014Metabolic Signatures for Alzheimer's Disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2007 - 2011Epidemiology of Dementia in Cache County, Utah
ResearchCo Investigator · Awarded by National Institutes of Health · 1994 - 2011NIH State of the Science Conference on Preventing Alzheimer's Disease and Cognitive Decline
ResearchInvestigator · Awarded by Agency for Healthcare Research and Quality · 2008 - 2010Same
ResearchInvestigator · Awarded by National Institutes of Health · 1989 - 2008Admin Suppl - Novel therapeutics in Parkinson's disease: Identification of alpha-synuclein binding peptides by screening
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2003Manipulation of polyglutamine-protein interactions
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2003NINDS Administrative supplement for FDA-approved compound screens for neurodegeneration
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2003Genetic Epidemiolgy Of Alzheimer Disease In Twins
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1996 - 1998Arly Genes And Kindling Development
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1996Early Gene And Kindling Development
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1996Early Genes And Kindling Development
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1996Early Genes And Kindling Development - Cida
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1996External Relationships
- Revivo Pharma
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.